Healthcare entity

Macau Health Bureau

organization

regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ANKTIVA, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.

Last mentioned: Mar 25, 2026

Entity pulse

Recent coverage · Macau Health Bureau

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Macau Health Bureau

regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ANKTIVA, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 6.6. We currently track 1 Healthcare story that mention Macau Health Bureau, all published on March 25, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Macau Health Bureau. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Expected Regional Launch

    Anticipated availability of ANKTIVA in Macau oncology centers.

  2. Macau SAR Approval

    Macau Health Bureau grants regulatory clearance for ANKTIVA.

  3. U.S. Commercial Launch

    ImmunityBio begins commercial distribution of ANKTIVA in the U.S.

  4. U.S. FDA Approval

    ANKTIVA receives first-ever approval for NMIBC in the United States.

Stories mentioning Macau Health Bureau 1

Health Policy Positive

ImmunityBio Secures Macau Approval for ANKTIVA, Eyeing Chinese Oncology Market

ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.

2 sources

Source: finance.yahoo.com · insidermonkey.com

Macau Health Bureau is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.